Avalon GloboCare Corp. announced that the Company has signed a memorandum of understanding with Lu Daopei Hematology Institute to co-develop precision companion diagnostics (CDx) for chimeric antigen receptor (CAR)-T cell therapies. To further strengthen its CDx development capabilities, Avalon has appointed Dr. Hongxing Liu, M.D., M.S., Executive President of LDHI and a world-renowned expert in precision diagnostics for hematologic malignancies, to its Scientific and Clinical Advisory Board.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4301 USD | -2.03% | -4.51% | -10.95% |
1st Jan change | Capi. | |
---|---|---|
-10.95% | 4.87M | |
-15.37% | 8.55B | |
+64.16% | 4.23B | |
+3.72% | 2.68B | |
-2.45% | 2.61B | |
-54.53% | 1.82B | |
-19.65% | 1.66B | |
-21.18% | 1.42B | |
+15.98% | 1.19B | |
-48.13% | 1.05B |
- Stock Market
- Equities
- ALBT Stock
- News Avalon GloboCare Corp.
- Avalon GloboCare Corp. Appoints Hongxing Liu to Scientific and Clinical Advisory Board